Poster Exhibition -Cholangioca and Other Liver Neoplasm Poster Session, Hall 5B Background: Now, RFA has becoming an important practice of HCC therapy. In this study, we evaluated whether RFA therapy for metastatic liver tumor has a beneficial effect on patients' survival. Methods: Forty six patients were treated by RFA for metastatic liver tumor from July 2001 through February 2008 in our hospital, of the 46, 33 patients were metastasis either form colon or stomach cancer. These 33 patients were analyzed in this investigation. Cumulative survival rate from initial RFA therapy was calculated by Kaplan-Meier method. Predictive factors for survival were identified using Cox proportional hazard regression model. Results: The mean age of the 33 patients were 64. 6 (range, 40-79) . The mean size of the tumor is 28mm (range,8-70mm) and the numbers of tumor foci are 2.7 nodules range,1 18. The survival rates of patients treated by RFA were 49.5% at 3 years and 31.8% at 5 years in colon cancer, 15.6% at 3 years and 15.6% at 5 years in gastric cancer. In this series of 33 patients, primary cancer: colon (P=0.002 odds ratio 0.132 95%CI 0.037-0.473), younger patients ( 64) (P=0.041 odds ratio 0.312 95%CI 0.102-0.955) and multiagent chemotherapy (P=0.012 odds ratio 0.223 95% CI 0.069-0.723) were significantly correlated with better survival. Conclusion: The survival of patients treated by RFA for metastatic colon cancers had better survival than those of gastric cancers. In addition, good indication of RFA is for metastatic colon cancers, younger patients and has to be treated by multiagent chemotherapies.